INSUBCONTINENT EXCLUSIVE:
New Delhi: Alembic Pharmaceuticals Tuesday reported 30 per cent rise in consolidated net profit to Rs 169.83 crore for quarter ended
December 31, 2018 mainly on account of robust sales in US.
The company had posted a net profit of Rs 130.60 crore in year-ago period,
Alembic Pharma said in a filing to BSE.
Consolidated revenue from operations stood at Rs 1,018.15 crore in reported quarter as against Rs
840.02 crore in December quarter 2017.
"The growth in quarter was attributed to a strong performance in US and international business," MD
Pranav Amin said.
The company's formulation as well as active pharmaceutical ingredient (API) facilities were successfully approved by
USFDA during quarter, he added.
The US business grew 42 per cent to Rs 308 crore for December quarter 2018 as against Rs 218 crore in
year-ago period, it said.
Shares of Alembic Pharma closed at Rs 587.80 per scrip on BSE, down 0.60 per cent from previous close.
